Cite

Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran.

MLA

Zijlstra, Laurien E., et al. “Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran.” Mayo Clinic Proceedings, vol. 95, no. 1, Jan. 2020, pp. 12–14. EBSCOhost, https://doi.org/10.1016/j.mayocp.2019.11.010.



APA

Zijlstra, L. E., Trompet, S., Mooijaart, S. P., van Buren, M., & Jukema, J. W. (2020). Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran. Mayo Clinic Proceedings, 95(1), 12–14. https://doi.org/10.1016/j.mayocp.2019.11.010



Chicago

Zijlstra, Laurien E, Stella Trompet, Simon P Mooijaart, Marjolijn van Buren, and J Wouter Jukema. 2020. “Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran.” Mayo Clinic Proceedings 95 (1): 12–14. doi:10.1016/j.mayocp.2019.11.010.